General Information of Drug (ID: DM1XEJV)

Drug Name
glycodeoxycholic acid Drug Info
Synonyms glycodeoxycholate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3035026
ChEBI ID
CHEMBL258605
CAS Number
CAS 360-65-6
TTD Drug ID
DM1XEJV
VARIDT Drug ID
DR00948

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTP
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [5]
Folic Acid DMEMBJC Colorectal carcinoma Approved [6]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [7]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [8]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [9]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [10]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [11]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [12]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [2]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [13]
Taurocholic Acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [14]
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [14]
Drug(s) Affected By Bile acid receptor (NR1H4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [15]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [16]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [17]
Quercetin DM3NC4M Obesity 5B81 Approved [18]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [4]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [19]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [16]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [17]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [20]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Apical sodium-dependent bile acid transporter (SLC10A2) DT7JELC NTCP2_HUMAN Substrate [2]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4714).
2 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
5 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
6 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
7 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
8 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
9 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
10 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
11 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
12 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
13 Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
14 Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
15 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
16 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
17 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
18 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
19 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
20 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
21 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.